Elthera is focused on developing innovative immunotherapies that target the L1 cell adhesion molecule (L1CAM), a protein that is overexpressed in various aggressive tumors, including pancreatic, ovarian, breast, lung, and colorectal cancers. The presence of L1CAM is associated with increased tumor malignancy, promoting processes such as cellular proliferation, metastasis, and resistance to chemotherapy. Elthera's approach involves creating therapeutic molecules that can bind to L1CAM on tumor cells while simultaneously engaging specialized immune cells. This dual binding mechanism aims to recruit and activate these immune cells to effectively destroy cancer cells and inhibit tumor progression.

In addition to their therapeutic development, Elthera has secured a worldwide exclusive license for the intellectual property related to anti-L1CAM antibodies. This license encompasses all relevant materials and know-how, including additional undisclosed monoclonal antibodies and research tools. By leveraging this exclusive intellectual property, Elthera aims to enhance and expedite the development of their anti-L1CAM-based antibody therapies, positioning themselves at the forefront of precision medicine for patients with highly aggressive malignancies.

Switzerland

Elthera AG is a Swiss biopharmaceutical start-up company bringing together experienced pharma and biotech executives with cutting-edge academic researchers to develop proprietary, first-in-class oncology drugs using a personalized health care approach.  Elthera AG is developing antibodies against a novel target whose expression is strongly correlated with an aggressive tumor phenotype and poor prognosis in various types of cancer.  By combining targeted therapies with companion diagnostics, Elthera AG is aiming at providing new personalized treatment options for patients with the most aggressive malignancies

Elthera

Company Details